Orthocell Limited (ASX:OCC)’s stock price fell 2.1% during trading on Friday . The company traded as low as A$0.48 ($0.34) and last traded at A$0.48 ($0.34), 376,492 shares traded hands during mid-day trading. The stock had previously closed at A$0.49 ($0.34).
The company has a market capitalization of $73.57 million and a P/E ratio of -9.69. The business has a 50 day moving average of A$0.48 and a 200 day moving average of A$0.47.
Orthocell Company Profile (ASX:OCC)
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and related technologies for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia and Poland. The company's principal products include CelGro, a naturally derived collagen medical device for soft tissue repair that is under clinical trials for use as an augment to the surgical repair of tendons, peripheral nerves, bones, and articular cartilage; and Ortho-ATI, an autologous tenocyte implantation for chronic treatment resistant tendon injuries.
Further Reading: Using other technical indicators with support levels
Receive News & Ratings for Orthocell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthocell and related companies with MarketBeat.com's FREE daily email newsletter.